DiaKine Therapeutics, Inc. Drug Improves Type 2 Insulin Action; Reduces Harm of Fat in Preclinical Study

BANFF, Alberta--(BUSINESS WIRE)--Results of a preclinical study involving DiaKine Therapeutics’ lead drug candidate Lisofylline (LSF) indicate the compound may reduce two key risk factors for type 2 diabetes.